Related Experiment Video
Updated: Feb 10, 2026

Apical Resection Mouse Model to Study Early Mammalian Heart Regeneration
Published on: January 23, 2016
Cell therapy trials for heart regeneration - lessons learned and future directions
1Department of Cardiovascular Surgery, Université Paris Descartes, Sorbonne Paris Cité, INSERM U-970, Hôpital Européen Georges Pompidou, Paris, France. philippe.menasche@aphp.fr.
Cell therapy shows promise for heart regeneration in chronic cardiomyopathy, but efficacy requires further study. Future trials should focus on remuscularization or activating host repair pathways for better outcomes.
Area of Science:
- Cardiovascular Medicine
- Regenerative Medicine
- Stem Cell Therapy
Background:
- Cell therapy is being investigated for heart regeneration in chronic cardiomyopathy.
- Clinical trials have used various cell types, including mesenchymal stem cells and cardiac-committed cells.
Purpose of the Study:
- To review outcomes of cell therapy trials for heart regeneration.
- To provide perspectives for future cell-based regenerative trials.
Main Methods:
- Categorization of trials based on cell type: noncardiac stem cells vs. cardiac-committed cells.
- Summary of main outcomes and lessons learned from completed studies.
Main Results:
- Cell therapy has demonstrated consistent safety in patients with chronic cardiomyopathy.
- The efficacy of cell therapies for heart regeneration remains elusive, requiring further investigation.
Conclusions:
- Future trials should optimize cell delivery, survival, and integration for remuscularization.
- Alternatively, focusing on activating endogenous repair pathways via paracrine signaling or secretome administration offers flexibility.
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Heart Failure VI: Adjunct Therapies
Anatomy of the Heart
Trial and Error and Algorithm
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...

